Specific protein degradation is getting explored as an alternative system in cancer, whereby the natural protein degradation program is co-opted for therapeutic reasons. Not long ago formulated novel molecules identified as proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. 1 ligand binds towards the https://www.directivepublications.org/journal-of-clinical-breast-cancer/